Cabozantinib may be a viable first-line treatment in metastatic renal cell collecting duct carcinoma
1. Objective response rate was 35%, with 1 patient showing a complete response and 7 showing a...
Read More
Oncology
Elevated neutrophil-lymphocyte ratio associated with poor prognosis for head and neck cancer
1. This single-centred, observational cohort study demonstrated that among patients with head and...
Read More
Pembrolizumab did not show overall survival benefit in patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer
1. The median overall survival for pembrolizumab versus chemotherapy was not statistically...
Read More
Neoadjuvant nivolumab plus chemotherapy increases event-free survival in resectable non-small-cell lung cancer
1. Neoadjuvant nivolumab plus chemotherapy led to a longer event-free survival and higher...
Read More
Exercise during early-stage breast cancer decreases health care utilization
1. Patients in the control group had higher mean health care utilization costs across the...
Read More
Adjuvant chemotherapy associated with an improved overall survival for patients with locally advanced gastric cancer
1. In this retrospective cohort study, 462 patients with locally advanced gastric cancer...
Read More
Neonatal Hypoglycemia and Academic Performance in Childhood
For a study, researchers sought to explore the hypothesis that neonatal hypoglycemia is related to...
Read More
Prophylactic Oral Dextrose Gel and Neurosensory Impairment at 2-Year Follow-up of Participants in the hPOD Randomized Trial
For a study, researchers sought to investigate the effects of preventive dextrose gel on...
Read More
Echocardiographic Meas. of LA Function & Size With Dementia
For a study, researchers sought to look at the relationship between (Left Atrial) LA function and...
Read More
#VisualAbstract: Neoadjuvant HD201 shows similar efficacy to referent trastuzumab for ERBB2-positive breast cancer
Click to read this study in JAMA Oncology.
Read More
Carotuximab addition to pazopanib does not improve survival in advanced angiosarcoma patients
1. Carotuximab in tandem with pazopanib did not show improvement in progression-free survival or...
Read More
Adherence to pre-treatment imaging guidelines for staging in rectal cancer is increasing, but a gap still remains
1. Adherence to the guidelines increased from 38% to 56% between Fall 2016 and 2019; and from 37%...
Read More
Induction chemotherapy with paclitaxel, cisplatin and capecitabine showed promising clinical and safety response to treat advanced nasopharyngeal carcinoma
1. The failure-free-survival at 3 years for induction chemotherapy with paclitaxel, cisplatin and...
Read More
Obesity may be associated with better response to immune checkpoint blockade therapy
1. In this study, patients who were obese or overweight had better survival compared to normal...
Read More
Trastuzumab deruxtecan associated with lower risk of metastatic breast cancer progression
1. Compared to trastuzumab emtansine, trastuzumab deruxtecan is associated with a lower risk of...
Read More
Darolutamide with chemotherapy and androgen-deprivation therapy improves overall survival in metastatic hormone-sensitive prostate cancer
1. Overall survival was significantly longer in patients taking darolutamide in tandem with...
Read More
Trastuzumab deruxtecan superior to trastuzumab emtansine in patients with metastatic HER2 breast cancer
1. Longer progression-free survival was found in patients taking trastuzumab deruxtecan compared...
Read More
Darolutamide improves overall survival in patients with hormone-sensitive prostate cancer
1. Patients with hormone-sensitive prostate cancer receiving darolutamide, an androgen-receptor...
Read More
Religious attendance may be correlated with cancer screening utilization
1. This study found there was a positive association between religious attendance and cancer...
Read More
Examining Age Disparity in Clinical Trial Understanding
“Older adults with cancer are underrepresented in clinical trials, despite comprising the majority...
Read More